6-fluoro-2-acetonaphthone | 33627-02-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-fluoro-2-acetonaphthone
• 英文别名: 1-(6-Fluoronaphthalen-2-yl)ethanone
• CAS: 33627-02-0
• 化学式: C₁₂H₉FO
• 分子量: 188.201
• InChiKey: TXXWLEREQYRORU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-fluoro-2-acetonaphthone 在 potassium bromate 、 水 、 potassium bromide 作用下， 以 乙醇 为溶剂， 反应 4.75h， 生成 (6-Fluor-2-naphthacyl)-benzoat
  参考文献：
  名称：

  Thirunarayanan; Vanangamudi; Sathiyendran, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2011, vol. 50, # 4, p. 593 - 604

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氟萘 在 氢氟酸 作用下， 生成 6-fluoro-2-acetonaphthone
  参考文献：
  名称：

  Acylation of naphthalenes

  摘要：

  在2-或β-位置上带有电子给予取代基团的萘可以通过在基本无水氢氟酸中使用酰化试剂进行酰化反应，以高选择性地在6-位置上发生反应，氢氟酸既起催化剂又起溶剂的作用。

  公开号：

  US04593125A1

文献信息

• Stereospecific Nickel-Catalyzed Borylation of Secondary Benzyl Pivalates
  作者：R. Martin、R. Martin-Montero、T. Krolikowski、C. Zarate、R. Manzano

  DOI：10.1055/s-0036-1590962

  日期：2017.12

  A stereoselective nickel-catalyzed direct borylation of enantioenriched secondary benzyl pivalates is described. This methodology is characterized by an intriguing cooperativity of simple nickel and copper salts to promote the targeted C–B bond formation under mild reaction conditions. Unlike classical SN2-type processes, this protocol occurs with a neat retention of configuration, resulting in synthetically

  描述了立体选择性镍催化直接硼酸化对映体富集的仲新戊酸苄酯。该方法的特点是简单的镍盐和铜盐具有有趣的协同作用，可在温和的反应条件下促进目标 C-B 键的形成。与经典的 SN2 型工艺不同，该协议以整洁的配置保留发生，从而产生具有优异立体化学保真度的合成通用苄基硼酸酯。
• 3-Substituted Propanamine Compounds
  申请人：Park Chun-Eung

  公开号：US20100311789A1

  公开（公告）日：2010-12-09

  Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.

  本发明涉及由以下结构式(I)表示的混合或对映富集的3-取代丙胺化合物或其药学上可接受的盐。本发明还涉及含有该化合物的制药组合物。所述化合物对于治疗中枢神经系统疾病，如抑郁症、焦虑症和疼痛障碍，具有有用性。
• 3-SUBSTITUTED PROPANAMINE COMPOUNDS
  申请人：Park Chun-Eung

  公开号：US20120046312A1

  公开（公告）日：2012-02-23

  Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.

  本文披露了由以下结构式（I）表示的外消旋或对映富集的3-取代丙胺化合物或其药学上可接受的盐。本文还披露了含有该化合物的药物组合物。该化合物对于治疗中枢神经系统疾病，如抑郁症、焦虑症和疼痛障碍非常有用。
• Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same
  申请人：Yale University

  公开号：US20140302523A1

  公开（公告）日：2014-10-09

  The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of a compound to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition.

  本发明包括一些化合物，这些化合物有助于扰乱或破坏跨膜或胞内蛋白的功能，其中化合物与跨膜或胞内蛋白的结合诱导跨膜或胞内蛋白的蛋白酶体降解。本发明还包括一种诱导跨膜或胞内蛋白的蛋白酶体降解的方法。本发明还包括一种鉴定或验证感兴趣蛋白作为治疗疾病状态或病情的治疗靶点的方法。
• Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors
  作者：Ki-Ho Lee、Chun-Eung Park、Kyung-Hyun Min、Yong-Je Shin、Coo-Min Chung、Hui-Ho Kim、Hae-Jeoung Yoon、Won-Kim、Eun-Ju Ryu、Yu-Jin Shin、Hyun-Sik Nam、Jeong-Woo Cho、Hee-Yoon Lee

  DOI：10.1016/j.bmcl.2010.07.021

  日期：2010.9

  A series of 3-aryl-3-azolylpropan-1-amines was prepared and screened for its capability of inhibiting monoamine reuptake. Analogs with nanomolar potency, good human in vitro microsomal stability, and low drug-drug interaction potential were described. In vivo models were used to evaluate the compound 19r for antidepressive, anxiolytic, and analgesic activity. (C) 2010 Elsevier Ltd. All rights reserved.